美国 · SEC FORM 4
ImageneBio, Inc.
IMA · Nasdaq · CIK 0001835579 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
7 同一窗口内观察到的 Form 4 交易行
2 sales · 5 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-12-24 · SLATTERY JOSEPH P.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 32,852
- 上期报告
- 34,601
- 日均成交量
- 17,299
- 回补天数
- 1.9
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-12-24 | SLATTERY JOSEPH P | 买入 (P) | Common Stock | 16,000 | USD 5.99 | USD 95,840 | SEC 申报 ↗ |
| 2025-07-25 | Stampacchia Otello | 买入 (P) | Common Stock | 267,556 | USD 29.90 | USD 7,999,924 | SEC 申报 ↗ |
| 2025-07-25 | Bonita David P | 买入 (P) | Common Stock | 83,611 | USD 29.90 | USD 2,499,969 | SEC 申报 ↗ |
| 2022-06-24 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLC | 买入 (P) | Common Stock | 162,000 | USD 4.96 | USD 803,975 | SEC 申报 ↗ |
| 2022-06-24 | Bonita David P | 买入 (P) | Common Stock | 162,000 | USD 4.96 | USD 803,975 | SEC 申报 ↗ |
| 2022-06-23 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLC | 买入 (P) | Common Stock | 23,419 | USD 3.71 | USD 86,884 | SEC 申报 ↗ |
| 2022-06-23 | Bonita David P | 买入 (P) | Common Stock | 23,419 | USD 3.71 | USD 86,884 | SEC 申报 ↗ |
| 2022-06-22 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLC | 买入 (P) | Common Stock | 66,806 | USD 3.55 | USD 237,161 | SEC 申报 ↗ |
| 2022-06-22 | Bonita David P | 买入 (P) | Common Stock | 66,806 | USD 3.55 | USD 237,161 | SEC 申报 ↗ |
| 2021-03-30 | FORMELA JEAN FRANCOIS | 买入 (P) | Common Stock | 125,000 | USD 16.00 | USD 2,000,000 | SEC 申报 ↗ |
| 2021-03-30 | Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Fund XI, L.P.; Atlas Venture Opportunity Fund I, L.P. | 买入 (P) | Common Stock | 125,000 | USD 16.00 | USD 2,000,000 | SEC 申报 ↗ |
| 2021-03-30 | Bonita David P | 买入 (P) | Common Stock | 423,400 | USD 16.00 | USD 6,774,400 | SEC 申报 ↗ |
| 2021-03-30 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLC | 买入 (P) | Common Stock | 423,400 | USD 16.00 | USD 6,774,400 | SEC 申报 ↗ |
| 2021-03-30 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLC | 买入 (P) | Common Stock | 423,400 | USD 16.00 | USD 6,774,400 | SEC 申报 ↗ |
| 2021-03-30 | Bonita David P | 买入 (P) | Common Stock | 423,400 | USD 16.00 | USD 6,774,400 | SEC 申报 ↗ |
Form 4 申报证据
10 transaction lines in the latest 365-day window; 84 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-14 | Yarema Kristin | 奖励／授予 (A) | Common Stock | 254,800 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-14 | Grant-Huerta Yanina | 奖励／授予 (A) | Common Stock | 104,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-25 | Yarema Kristin | 期权行权／转换 (M) | Common Stock | 38,376 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (9 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-14 | Yarema Kristin | 奖励／授予 (A) | Common Stock | 254,800 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-14 | Grant-Huerta Yanina | 奖励／授予 (A) | Common Stock | 104,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-25 | Yarema Kristin | 期权行权／转换 (M) | Common Stock | 38,376 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-25 | Yarema Kristin | J (J) | Common Stock | 115,129 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-17 | Lally Robert B | 卖出 (S) | Common Stock | 1,525 | USD 5.34 | USD 8,144 | SEC 申报 ↗ |
| 2026-07-16 | Lally Robert B | 卖出 (S) | Common Stock | 1,671 | USD 5.50 | USD 9,190 | SEC 申报 ↗ |
| 2026-03-16 | Yarema Kristin | 奖励／授予 (A) | Common Stock | 85,400 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-30 | Butler Erin | 奖励／授予 (A) | Common Stock | 22,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-24 | SLATTERY JOSEPH P | 买入 (P) | Common Stock | 16,000 | USD 5.99 | USD 95,840 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | IMA |
| CIK | 0001835579 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 84 transaction lines from 2021-03-30 to 2026-08-14 21 P purchase lines · 11 S sale lines · 52 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.